Skip to content

    Melanoma/Skin Cancer Health Center

    Font Size

    Melanoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage I Melanoma Treatment

    Standard Treatment Options for Stage I Melanoma

    Standard treatment options for stage I melanoma include the following:

    Recommended Related to Melanoma/Skin Cancer

    Should I Consider a Clinical Trial for Metastatic Melanoma?

    It's natural to want the very latest treatments when you have a serious health condition like metastatic melanoma. One way to get those cutting-edge drugs is to sign up for a clinical trial. Before you enroll, you'll want to learn all you can about the study, what's being tested, and the risks and benefits. Work with your doctor to get that information and make sure the trial is a good fit for you. But first, get to know what's involved.

    Read the Should I Consider a Clinical Trial for Metastatic Melanoma? article > >

    1. Excision with or without lymph node management.


    Evidence suggests that lesions no thicker than 2 mm may be treated conservatively with radial excision margins of 1 cm.

    Depending on the location of the melanoma, most patients can now have the excision performed on an outpatient basis.

    Evidence (excision):

    1. A randomized trial compared narrow margins (1 cm) with wide margins (≥3 cm) in patients with melanomas no thicker than 2 mm.[1,2][Level of evidence: 1iiA]
      • No difference was observed between the two groups in the development of metastatic disease, disease-free survival (DFS), or overall survival (OS).
    2. Two other randomized trials compared 2-cm margins with wider margins (4 cm or 5 cm).[3,4][Level of evidence:1iiA]
      • No statistically significant difference in local recurrence, distant metastasis, or OS was found; the median follow-up was at least 10 years for both trials.
    3. In the Intergroup Melanoma Surgical Trial, the reduction in margins from 4 cm to 2 cm was associated with both of the following:[5][Level of evidence: 1iiA]
      • A statistically significant reduction in the need for skin grafting (from 46% to 11%; P < .001).
      • A reduction in the length of hospital stay.
    4. A multicenter, phase III randomized trial (SWOG-8593) of patients with high-risk stage I primary limb melanoma did not show a DFS or OS benefit from isolated limb perfusion with melphalan, when compared with surgery alone.[6,7]

    Lymph node management

    Elective regional lymph node dissection is of no proven benefit for patients with stage I melanoma.[8]

    Lymphatic mapping and sentinel lymph node biopsy (SLNB) for patients who have tumors of intermediate thickness and/or ulcerated tumors may identify individuals with occult nodal disease. These patients may benefit from regional lymphadenectomy and adjuvant therapy.[6,9,10,11]

    Evidence (immediate lymphadenectomy vs. observation with delayed lymphadenectomy):

    1. The International Multicenter Selective Lymphadenectomy Trial (MSLT-1 [JWCI-MORD-MSLT-1193]) included 1,269 patients with intermediate-thickness (defined as 1.2 mm-3.5 mm in this study) primary melanomas.[12][Level of evidence: 1iiB]
      • There was no melanoma-specific survival advantage (primary endpoint) for patients randomly assigned to undergo wide excision plus SLNB, followed by immediate complete lymphadenectomy for node positivity versus nodal observation and delayed lymphadenectomy for subsequent nodal recurrence at a median of 59.8 months.
      • This trial was not designed to detect a difference in the impact of lymphadenectomy in patients with microscopic lymph node involvement.
    2. The Sunbelt Melanoma Trial (UAB-9735 [NCT00004196]) was a phase III trial to determine the effects of lymphadenectomy with or without adjuvant high-dose interferon alpha-2b versus observation on DFS and OS in patients with submicroscopic sentinel lymph node (SLN) metastasis detected only by the polymerase chain reaction assay (i.e., SLN negative by histology and immunohistochemistry).
      • No survival data have been reported from this study.
    1 | 2
    Next Article:

    Today on WebMD

    Malignant melanoma
    About 40-50 percent of those who live to be 65 may get it. Here’s how to spot early.
    Woman checking out tan lines
    There’s a dark side to that strive for beauty. See them here.
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Lung cancer xray
    See it in pictures, plus read the facts.
    12 Ways to Protect Your Skin from Melanoma
    precancerous lesions slideshow
    Do You Know Your Melanoma ABCs
    15 Cancer Symptoms Men Ignore
    screening tests for men
    Vitamin D
    Is That Mole Skin Cancer
    Brilliant sun rays